Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis

作者：Jean Galtier, Pierre Sesques, Vivien Dupont, Emmanuel Bachy, Roberta Di Blasi, Catherine Thieblemont, Gabriel Brisou, Thomas Gastinne, Guillaume Cartron, François‐Xavier Gros, Franck Morschhauser, Axel André, Jacques‐Olivier Bay, Magalie Joris, Aline Schmidt, Audrey Demailly, Steven Le Gouill, Roch Houot, Krimo Bouabdallah, Vincent Camus · 发表于：Blood · 年份：2025 · DOI：10.1182/blood-2025-3733 · 被引用次数：1 · 研究领域：CAR-T cell therapy research、Lymphoma Diagnosis and Treatment、Cutaneous lymphoproliferative disorders research

Abstract Background : Primary mediastinal B-cell lymphoma (PMBL) is a rare subtype of large B-cell lymphoma that usually responds well to frontline immunochemotherapy but has historically had a poor prognosis in the relapsed/refractory (R/R) setting. Although anti-CD19 CAR-T cell therapy has shown a high rate of sustained remissions in R/R PMBL, the clinical features and outcomes of patients (pts) who relapse after this treatment are still not well understood, despite representing a new unmet medical need. This study aimsto describe the characteristics, management, and post–CAR-T cell outcomes of these pts with a particular focus on responses to subsequent lines of therapy. Methods The CARTHYM study previously examined outcomes in 82 pts with PMBL who received anti-CD19 CAR-T cell therapy in France between October 2018 and February 2024, within the French DESCAR-T registry (NCT04328298). For this analysis, we included all pts who experienced disease progression after CAR-T cell therapy. The primary objective was to assess 1-year overall survival (OS) from the time of progression. Secondary objectives included evaluating responses to subsequent lines of treatment and their associated 1-year progression-free survival (PFS). Results: Among 82 patients with R/R PMBL treated with anti-CD19 CAR-T cells, 27 (33%) experienced disease progression and comprised the study population. Of these, 14 (52%) received axi-cel, 11 (40%) tisa-cel, and 2 (7%) liso-cel. The median age at infusion ...